|Description||E2609, developed by Eisai Inc, is a novel, small molecule, BACE1 inhibitor that has been shown in nonclinical studies to inhibit the production of Aβ40 and Aβ42 in brain, reducing Aβ in cerebrospinal fluid and plasma after oral dosing. Phase 2|
|Brife Description||BACE1 protein inhibitor|
|Storage||Store in a cool and dry place and at 0 - 4℃ for short term (days to weeks) or -46℃ for long term (months to years).|
|Current Developer||Eisai Inc; GE Healthcare|
Rafabegron is a potent and selective beta3-adrenoceptor agonist.
TAK-070, under the IUPAC name 2-Naphthaleneethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-1,2,3,4-tetrahydro-N,N-dimethyl-, hydrochloride, hydrat...
E2609, developed by Eisai Inc, is a novel, small molecule, BACE1 inhibitor that has been shown in nonclinical studies to inhibit the production of Aβ40 and Aβ42...
AZD3293, a spiro compound, has been found to be a β-secretase inhibitor that has good blood-brain barrier penetration and could probably be significant in studi...
AZD3839, also called CHEMBL2177913, as a a potent BACE1 inhibitor it is a clinical candidate for the treatment of Alzheimer's disease. Studies indicate that the...
An inhibitor of β-site amyloid precursor protein-cleaving enzyme (BACE)
VTP-37948, also called BI 1181181, being clinically developed with Boehringer Ingelheim and Vitae Pharmaceuticals, is a is an inhibitor targeted to the catalyti...
Verubecestat, a iminothiadiazine dioxide compound, is an oral BACE1 inhibitor originated by Merck & Co. It can bind significantly to β-secretase. Verubecestat h...
LY2886721, under the IUPAC name N-(3-(2-amino-4a,5,7,7a-tetrahydro-4H-furo(3,4-d)(1,3)thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide, is the first oral sma...
HPP854, developed by High Point Pharmaceuticals, is a small molecule BACE1 protein inhibitor. Phase 1
This active molecular is a potent BACE1 inhibitor that is a potential target for the treatment of Alzheimer's disease. AMG-8718 produced significantly reduction...
CTS-21166, the selective BACE1 inhibitor whose structure is not revealed, reduce brain Aβ levels by over 35% and plaque load by 40%. Phase 1 IC50=1.2–3.6 nM (ce...
PF-05297909, is a BACE inhibitor developed by Pfizer. Phase 1
RG7129, developed by Roche, inhibit BACE to treat Alzheimer's disease. Phase-I
LY2811376, under the IUPAC name (4S)-4-(2,4-difluoro-5-pyrimidin-5-ylphenyl)-4-methyl-5,6-dihydro-1,3-thiazin-2-amine, is the first orally available non-peptidi...
Lanabecestat, also referred to AZD3293,is an orally active and highly permeable potent inhibitor of human β-secretase 1 in clinical development for the treatmen...
AZD3839, with the potential to treat Alzheimer’s disease, was reported as a selective BACE1 inhibitor (IC50=4.8μM) for which concentration-dependent lowering of...
EGCG, also called Epigallocatechin gallate, under the IUPAC name [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxy...